ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
COVID vaccines

Biden's vaccine patent waiver just start of global supply challenge

Complex tech and limited components restrict production, drugmakers say

WASHINGTON/VIENNA/TOKYO -- President Joe Biden's decision to back a waiver on patent protections for COVID-19 vaccines lowers one hurdle to broader production, but the specialized skills required in quality control and manufacturing look likely to create another bottleneck.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more